Detalhe da pesquisa
1.
Glycine decarboxylase activity drives non-small cell lung cancer tumor-initiating cells and tumorigenesis.
Cell
; 148(1-2): 259-72, 2012 Jan 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-22225612
2.
Clinical outcome and prognostic factors for Asian patients in Phase I clinical trials.
Br J Cancer
; 128(8): 1514-1520, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36797357
3.
Plain language summary of the updated results from the CROWN study comparing lorlatinib with crizotinib in people with advanced non-small-cell lung cancer.
Future Oncol
; 19(14): 961-973, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-37306090
4.
Risk factors for immune-related adverse events from anti-PD-1 or anti-PD-L1 treatment in an Asian cohort of nonsmall cell lung cancer patients.
Int J Cancer
; 150(4): 636-644, 2022 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34562273
5.
Dendritic cell therapy with CD137L-DC-EBV-VAX in locally recurrent or metastatic nasopharyngeal carcinoma is safe and confers clinical benefit.
Cancer Immunol Immunother
; 71(6): 1531-1543, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-34661709
6.
Low-dose pembrolizumab in the treatment of advanced non-small cell lung cancer.
Int J Cancer
; 149(1): 169-176, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33634869
7.
"Interchangeability" of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy.
Mod Pathol
; 33(1): 4-17, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31383961
8.
A randomized phase II trial evaluating the addition of low dose, short course sunitinib to docetaxel in advanced solid tumours.
BMC Cancer
; 20(1): 1118, 2020 Nov 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-33203399
9.
Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: final analysis of the GioTag study.
Future Oncol
; 16(34): 2799-2808, 2020 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-32854536
10.
Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial.
Lancet Oncol
; 20(12): 1691-1701, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31669155
11.
Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study.
Lancet Oncol
; 20(10): 1454-1466, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31405822
12.
Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag study.
Future Oncol
; 15(25): 2905-2914, 2019 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-31370698
13.
Somatic mutations and immune checkpoint biomarkers.
Respirology
; 24(3): 215-226, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30636374
14.
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
Lancet Oncol
; 19(4): 521-536, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29545095
15.
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
Lancet Oncol
; 19(12): 1654-1667, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30413378
16.
Third generation EGFR TKIs: current data and future directions.
Mol Cancer
; 17(1): 29, 2018 02 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-29455654
17.
Value of a molecular screening program to support clinical trial enrollment in Asian cancer patients: The Integrated Molecular Analysis of Cancer (IMAC) Study.
Int J Cancer
; 142(9): 1890-1900, 2018 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28994108
18.
Discovering novel SNPs that are correlated with patient outcome in a Singaporean cancer patient cohort treated with gemcitabine-based chemotherapy.
BMC Cancer
; 18(1): 555, 2018 May 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-29751792
19.
Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study.
Future Oncol
; 14(27): 2861-2874, 2018 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-30336693
20.
Global named patient use program of afatinib in advanced non-small-cell lung carcinoma patients who progressed following prior therapies.
Future Oncol
; 14(15): 1477-1486, 2018 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-29376400